Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amiselimod (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Bausch Health Companies; Salix Pharmaceuticals

Most Recent Events

  • 29 Aug 2025 Number of arms changed from 3 to 4. Other arm: Open Label Extension Period added to study protocol.
  • 28 Aug 2025 Status changed from active, no longer recruiting to completed.
  • 25 Sep 2024 This trial has been completed in Slovakia (Global end date: 2024-09-03) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top